Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hygtia Therapeutics
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Hygtia Therapeutics is an innovative biotechnology company dedicated to developing breakthrough treatments for autoimmune and central nervous system (CNS) disorders. Founded in August 2025 and incubated by Fosun Pharma and the Shenzhen Pengfu Fund of Fosun Health Capital, the company focuses on a global product strategy to introduce and develop "best-in-class" therapeutic assets. Its lead program, ISM8969, is a highly potent, brain-penetrant small molecule NLRP3 inhibitor co-developed with Insilico Medicine, currently being advanced toward clinical trials for Parkinson’s disease. By leveraging its clinical development and commercialization expertise alongside innovative partnerships, Hygtia aims to provide breakthrough treatment options for neurodegenerative and inflammatory conditions. The company is strategically positioned within the Fosun Health ecosystem to accelerate the translation of scientific innovations into clinical practice.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Insilico MedicineFosun PharmaFosun Health Capital
Beyond the preview
Go deeper on Hygtia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hygtia Therapeutics.